We’ve been pounding the table over obesity drug stocks for quite some time.

Look at Structure Therapeutics (GPCR).

Start pulling in more than a part time job. In about 5-10 min a day you can make more than most sidehustles. Click here to check it out for just $1.

The first time we highlighted an opportunity in the stock, it traded at around $22 in late June. Today, it’s up to $66.40 after it unveiled the topline data for its GLP-1 drug aleniglipron, which topped competing offerings from Eli Lilly and Novo Nordisk.

Fueling more excitement, BMO Capital raised its stock price target to $130 with an outperform rating.  As noted by Investing.com, “The price target increase follows the release of positive Phase 2b data for Structure’s lead asset Aleniglipron, according to BMO Capital. BMO Capital has increased its probability of success in obesity for the drug to 70% from the previous 55%, bringing its peak adjusted sales forecast in the indication to $3.8 billion by 2035.”

Sincerely,

Ian Cooper